Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 1 (2004), Issue 2 (September)

1. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer.
   Int J Cancer, 112(2): 335-40. [Abstract] [Full-text]
2. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs.
   Int J Cancer, 112(2): 231-8. [Abstract] [Full-text]
3. Expression of transforming growth factor-beta 1 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts.
   Int J Cancer, 112(2): 213-8. [Abstract] [Full-text]
4. CYP1B1 expression in prostate is higher in the peripheral than in the transition zone.
   Cancer Lett, 215(1): 69-78. [Abstract] [Full-text]
5. Plasma levels of transforming growth factor-1beta and alpha2-macroglobulin before and after radical prostatectomy: association to clinicopathological parameters.
   Prostate, 61(3): 201-8. [Abstract] [Full-text]
6. Prostasomes are secreted from poorly differentiated cells of prostate cancer metastases.
   Prostate, 61(3): 291-7. [Abstract] [Full-text]
7. Restoration of fibroblast growth factor receptor2 suppresses growth and tumorigenicity of malignant human prostate carcinoma PC-3 cells.
   Prostate, 61(3): 236-42. [Abstract] [Full-text]
8. CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts.
   Prostate, 61(3): 228-35. [Abstract] [Full-text]
9. Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays.
   Prostate, 61(3): 215-27. [Abstract] [Full-text]
10. Trefoil factor 3 is overexpressed in human prostate cancer.
    Prostate, 61(3): 209-14. [Abstract] [Full-text]
11. Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors.
    Prostate, 61(3): 276-90. [Abstract] [Full-text]
12. Vitamin D receptor gene polymorphisms and disease free survival after radical prostatectomy.
    Prostate, 61(3): 267-75. [Abstract] [Full-text]
13. Lesions predictive for prostate cancer in a screened population: first and second screening round findings.
    Prostate, 61(3): 260-6. [Abstract] [Full-text]
14. Inhibitory effect of IL-6-induced neuroendocrine cells on prostate cancer cell proliferation.
    Prostate, 61(3): 253-9. [Abstract] [Full-text]
15. HPC2/ELAC2 polymorphism associated with Japanese sporadic prostate cancer.
    Prostate, 61(3): 248-52. [Abstract] [Full-text]
16. Epothilone induced cytotoxicity is dependent on p53 status in prostate cells.
    Prostate, 61(3): 243-7. [Abstract] [Full-text]
17. Glycemic index, glycemic load and risk of prostate cancer.
    Int J Cancer, 112(3): 446-50. [Abstract] [Full-text]
18. A novel DNA methyltransferase I-derived peptide eluted from soluble HLA-A*0201 induces peptide-specific, tumor-directed cytotoxic T cells.
    Int J Cancer, 112(3): 426-32. [Abstract] [Full-text]
19. Binding and interstitial penetration of liposomes within avascular tumor spheroids.
    Int J Cancer, 112(4): 713-21. [Abstract] [Full-text]
20. Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells.
    Int J Cancer, 112(4): 693-700. [Abstract] [Full-text]
21. Retinol, carotenoids and the risk of prostate cancer: a case-control study from Italy.
    Int J Cancer, 112(4): 689-92. [Abstract] [Full-text]
22. Immunohistochemical characterisation of the monoclonal antibody BLCA-38 for the detection of prostate cancer.
    Cancer Immunol Immunother, 53(11): 995-1004. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.